IGC Pharma has announced the expansion of its Phase 2 CALMA clinical trial to include the renowned GNA site in Colombia. This addition aims to enhance the genetic diversity of trial participants and support the company’s goal of advancing its Alzheimer’s treatment development.
The inclusion of the GNA site, recognized for its expertise in Alzheimer’s research, is expected to strengthen the trial’s data quality and contribute to the planned data readout in 2026. This move reflects IGC Pharma’s commitment to conducting comprehensive and inclusive clinical studies.
**Why this matters**
Expanding the trial to a prominent research center in Colombia helps increase participant diversity, which is crucial for understanding how treatments perform across different genetic backgrounds. This approach can improve the reliability and applicability of trial results, potentially accelerating the development of effective therapies for Alzheimer’s disease.
Source: NewsData